NO20034504D0 - Erytropoietin forbedrer in vivo kjemoterapiindusert toksisitet - Google Patents

Erytropoietin forbedrer in vivo kjemoterapiindusert toksisitet

Info

Publication number
NO20034504D0
NO20034504D0 NO20034504A NO20034504A NO20034504D0 NO 20034504 D0 NO20034504 D0 NO 20034504D0 NO 20034504 A NO20034504 A NO 20034504A NO 20034504 A NO20034504 A NO 20034504A NO 20034504 D0 NO20034504 D0 NO 20034504D0
Authority
NO
Norway
Prior art keywords
induced toxicity
erythropoietin
cytotoxic agent
vivo chemotherapy
improves
Prior art date
Application number
NO20034504A
Other languages
English (en)
Other versions
NO20034504L (no
Inventor
George Sigounas
Paul Mehlhop
Original Assignee
Univ East Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23082337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20034504(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ East Carolina filed Critical Univ East Carolina
Publication of NO20034504D0 publication Critical patent/NO20034504D0/no
Publication of NO20034504L publication Critical patent/NO20034504L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
NO20034504A 2001-04-09 2003-10-08 Erytropoietin forbedrer in vivo kjemoterapiindusert toksisitet NO20034504L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28262101P 2001-04-09 2001-04-09
PCT/US2002/011081 WO2002080676A1 (en) 2001-04-09 2002-04-08 Erythropoietin ameliorates chemotherapy-induced toxicity in vivo

Publications (2)

Publication Number Publication Date
NO20034504D0 true NO20034504D0 (no) 2003-10-08
NO20034504L NO20034504L (no) 2003-12-09

Family

ID=23082337

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20034504A NO20034504L (no) 2001-04-09 2003-10-08 Erytropoietin forbedrer in vivo kjemoterapiindusert toksisitet

Country Status (22)

Country Link
US (2) US20020169128A1 (no)
EP (1) EP1377164B1 (no)
JP (1) JP4428924B2 (no)
KR (1) KR100885525B1 (no)
CN (2) CN100379446C (no)
AT (1) ATE399020T1 (no)
AU (1) AU2002256133B2 (no)
BR (1) BR0208727A (no)
CA (1) CA2443025A1 (no)
DE (1) DE60227244D1 (no)
DK (1) DK1377164T3 (no)
ES (1) ES2309166T3 (no)
HU (1) HUP0303838A3 (no)
IL (3) IL158155A0 (no)
MX (1) MXPA03009182A (no)
NO (1) NO20034504L (no)
NZ (1) NZ528675A (no)
PL (1) PL373361A1 (no)
PT (1) PT1377164E (no)
RU (1) RU2296563C2 (no)
WO (1) WO2002080676A1 (no)
ZA (1) ZA200307803B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
CA2471363C (en) 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
KR101163683B1 (ko) 2003-05-12 2012-07-10 아피맥스, 인크. 에리스로포이에틴 수용체에 결합하는 신규의 펩티드
MXPA05012313A (es) * 2003-05-12 2006-04-18 Affymax Inc Peptidos que se unen al receptor de eritropoyetina.
DE602004028725D1 (de) * 2003-05-12 2010-09-30 Affymax Inc Neue poly(ethylenglycol) modifizierte erythropoietinagonisten und deren verwendungen
US7919118B2 (en) 2003-05-12 2011-04-05 Affymax, Inc. Spacer moiety for poly (ethylene glycol) modified peptide based compounds
US20080312201A1 (en) * 2004-09-10 2008-12-18 Patrick Fogarty Reduced Toxicity Methotrexate Formulations and Methods for Using the Same
WO2006060148A2 (en) * 2004-11-11 2006-06-08 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) * 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
CA2661054A1 (en) * 2006-08-22 2008-02-28 Chugai Seiyaku Kabushiki Kaisha Prophylactic and/or therapeutic agents for peripheral neuropathy
WO2008050836A1 (fr) * 2006-10-25 2008-05-02 Ajinomoto Co., Inc. Agent destiné à l'amélioration des effets secondaires d'un agent chimiothérapeutique
EP1992355A1 (en) * 2007-05-16 2008-11-19 Eberhardt Spanuth Pharmaceutical combination medication comprising NSAIDs or cytoxic drugs
US10695402B2 (en) 2017-03-16 2020-06-30 University Of Rochester Erythropoietin for gastrointestinal dysfunction
WO2022159414A1 (en) 2021-01-22 2022-07-28 University Of Rochester Erythropoietin for gastroinfestinal dysfunction

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859765A (en) * 1983-10-17 1989-08-22 Syntex (U.S.A.) Inc. Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture
US4863857A (en) * 1985-03-01 1989-09-05 Board Of Regents, The University Of Texas System Polypeptide complementary to peptides or proteins having an amino acid sequence or nucleotide coding sequence at least partially known
NZ215865A (en) * 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
IT210425Z2 (it) * 1987-01-22 1988-12-30 Erga Srl Portachiavi con mezzo di scrittura telescopico incorporato
US4853871A (en) * 1987-04-06 1989-08-01 Genex Corporation Computer-based method for designing stablized proteins
US4856871A (en) * 1987-08-31 1989-08-15 General Electric Company Replaceable laser and lens assembly
JP2632014B2 (ja) * 1988-03-03 1997-07-16 中外製薬株式会社 骨髄機能障害性貧血治療剤
US20020052309A1 (en) * 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury
US6719977B1 (en) * 1998-02-12 2004-04-13 The General Hospital Corporation Methods to potentiate cancer therapies
MXPA01011429A (es) * 1999-05-11 2003-09-10 Ortho Mcneil Pharm Inc Modelado farmacocinetico y farmacodinamico de administracion de eritropoyetina.
US6531121B2 (en) * 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs

Also Published As

Publication number Publication date
HUP0303838A2 (hu) 2004-03-01
NO20034504L (no) 2003-12-09
WO2002080676A1 (en) 2002-10-17
EP1377164B1 (en) 2008-06-25
NZ528675A (en) 2006-10-27
MXPA03009182A (es) 2004-02-17
RU2296563C2 (ru) 2007-04-10
PL373361A1 (en) 2005-08-22
ZA200307803B (en) 2005-02-09
IL158155A (en) 2009-12-24
US20020169128A1 (en) 2002-11-14
JP4428924B2 (ja) 2010-03-10
AU2002256133B2 (en) 2007-05-31
HUP0303838A3 (en) 2010-03-29
CN100379446C (zh) 2008-04-09
CN101152565A (zh) 2008-04-02
ATE399020T1 (de) 2008-07-15
CN1499927A (zh) 2004-05-26
CA2443025A1 (en) 2002-10-17
KR20030087064A (ko) 2003-11-12
ES2309166T3 (es) 2008-12-16
DK1377164T3 (da) 2008-10-13
PT1377164E (pt) 2008-09-30
JP2004532840A (ja) 2004-10-28
KR100885525B1 (ko) 2009-02-26
IL198783A0 (en) 2010-02-17
IL158155A0 (en) 2004-03-28
US20110195046A1 (en) 2011-08-11
DE60227244D1 (de) 2008-08-07
RU2003132584A (ru) 2005-04-10
BR0208727A (pt) 2005-05-10
EP1377164A4 (en) 2005-05-04
EP1377164A1 (en) 2004-01-07

Similar Documents

Publication Publication Date Title
IL198783A0 (en) Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
TR200401029T4 (tr) Asilfenil-üre türevleri, imalat yöntemleri ve ilaç maddesi olarak kullanımları
MXPA03006841A (es) 4-fluoro-n-indan-2-il-benzamida y su uso como producto farmaceutico.
NO20015584D0 (no) Lantidsvarende insulintrofiske peptider
TNSN06377A1 (en) Combinations of glycopyrrolate and beta2 adrenoceptor agonists
RS51569B (en) COMPOSITIONS CONTAINING CRYSTAL TRANS - (+/-) - DELTA-9-TETRAHYDROCANABINOL
SE0301882D0 (sv) New use I
DE502005010427D1 (de) Physiologisch aktive zusammensetzung gegen diabetes
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
BRPI0412851A (pt) benzamidazóis de n-metila-substituìdos
EA200300503A1 (ru) Новые лекарственные композиции на основе солей тиотропия и солей салметерола
DE60336664D1 (de) Nichtnukleosidische reverse-transkriptase-hemmer
MX2007000028A (es) Derivados de nicotinamida y su uso como agentes terapeuticos.
BRPI0410649A (pt) benzo(b) tiofeno 3-arilóxi e 3-heteroarilóxi substituìdos como agentes terapêuticos com atividade pi3k
SE0402762D0 (sv) Indazole sulphonamide derivatives
CO5560515A2 (es) Combinacion de productos activos fungicidas
ATE348630T1 (de) Verminderung der nebenwirkungen der chemotherapie in krebspatienten
MXPA02012730A (es) Uso de acido pamoico o uno de sus derivados o uno de sus analogos para la preparacion de un medicamento para el tratamiento de enfermedades caracterizadas por depositos de agregados de amiloide.
EE200300129A (et) Distamütsiini alfa-halogenoakrüloüülderivaadi kasutamine
ITMI20022394A1 (it) Uso di triiodotironina 3-solfato come farmaco ad attivita&#39; tireomimetica e relative formulazioni farmaceutiche.
UA95299C2 (ru) Профилактический или терапевтический агент против вирусного заболевания, вызванного вирусом гепатита с
SE0000303D0 (sv) Novel compounds
ATE479695T1 (de) Sulfopyranosylacylglycerol-derivate zur anwendung in kombination mit bestrahlung in einer tumor- radiotherapie
MXPA04005033A (es) Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes.
EP1930023A3 (en) Erythropoietin ameliorates chemotherapy-induced toxicity in vivo

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application